Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
Twist Bioscience Corp (TWST) is the issuer of common stock referenced in a notice filed for the account of Emily M. Leproust. The notice indicates an intent to sell 6,639 shares of TWST common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $923,261.83 as of August 21, 2026. Shares of common stock outstanding were reported as 62,707,424 as of that date; this is a baseline figure, not the amount being sold. The planned sale is related to restricted stock vesting and includes an amount to cover a tax obligation arising from settlement of a vested equity award distribution. The filing also lists several TWST common stock sales by Emily M. Leproust in the prior three months, each with specified share counts and dollar amounts.
Twist Bioscience Corp (TWST) received a Rule 144 notice relating to planned sales of its common stock by officer Paula Green through Fidelity Brokerage Services LLC on NASDAQ. The notice covers up to 1,360 shares, tied to restricted stock vesting used in part to satisfy tax obligations from a vested equity award. Over the prior three months, Paula Green reported several sales of Twist Bioscience common shares on specific dates with disclosed share amounts and dollar proceeds.
Twist Bioscience Corp (TWST) has a notice of proposed sale of common stock under Rule 144 for the account of Adam Laponis. The filing lists 1,965 shares of common stock to be sold, acquired via restricted stock vesting from the issuer as compensation on 08/20/2026. As of 08/21/2026, Laponis held 1,965 shares with an aggregate market value of $273,265.47, and Twist Bioscience had 62,707,424 shares outstanding. The filing notes that the sale includes shares necessary to cover tax obligations from settlement of a vested equity award.
Twist Bioscience Corp (TWST) received a Rule 144 notice indicating that officer Dennis H. Cho plans to sell up to 1,598 shares of common stock through Fidelity Brokerage Services LLC, with an indicated aggregate market value of $222,228.11, on or after August 21, 2026, on NASDAQ. The shares relate to restricted stock vesting on August 20, 2026, and the sale includes an amount necessary to cover a tax obligation arising from settlement of a vested equity award.
Over the prior three months, Dennis H. Cho reported multiple sales of Twist Bioscience common stock, including 14,205 shares sold on several dates with proceeds ranging from $874,47.34 to $1,853,098.75, plus smaller sales of hundreds of shares, all disclosed under Rule 144.
Twist Bioscience Corp (TWST) reported a planned sale of its common stock under Rule 144 for the account of officer Robert F. Werner. A brokerage firm filed to sell 669 shares, related to restricted stock vesting on 08/20/2026, with some shares covering a tax obligation from the vested equity award.
Werner also reported prior sales of common stock in the last three months totaling 3,014 shares across four transactions dated 05/21/2026, 05/26/2026, 06/08/2026, and 08/03/2026.
Twist Bioscience Corp (symbol TWST) received a notice that officer Patrick Finn plans to sell 4,046 shares of its common stock. The shares are tied to restricted stock vesting dated August 20, 2026, with the transaction described as compensation-related and executed through Fidelity Brokerage Services LLC on NASDAQ.
Over the prior three months, Patrick Finn reported sales of Twist Bioscience common stock on May 21, 2026 (4,160 shares), July 23, 2026 (2,238 shares), August 3, 2026 (2,888 shares), and August 18, 2026 (78,355 shares). The filing notes that the sale includes an amount needed to cover a tax obligation from the settlement of a vested equity award.
Twist Bioscience Corp (TWST) reported that President and COO Patrick John Finn exercised a stock option for 23,355 shares of common stock at an exercise price of $67.85 per share, eliminating this option position. On the same date, he sold a total of 78,355 shares of common stock in a series of transactions at weighted-average prices ranging from approximately $115.35 to $122.815 per share. These transactions were effected pursuant to a previously adopted Rule 10b5-1 trading plan dated May 18, 2026.
Twist Bioscience Corporation (TWST) reports that, under a Registration Rights Agreement dated February 11, 2026 with Invenra Inc., it is registering the resale of shares issuable to Invenra under a related Stock Purchase Agreement dated the same day. The company is filing a prospectus supplement to cover these resale shares. An opinion of Orrick, Herrington & Sutcliffe LLP regarding the validity of the shares is included as Exhibit 5.1.
Twist Bioscience Corporation (TWST) has filed a prospectus supplement registering for resale up to 35,114 shares of common stock issuable to a selling securityholder, Invenra Inc., under a Stock Purchase Agreement and related Registration Rights Agreement. These shares may be sold from time to time in various types of brokerage or privately negotiated transactions. Twist will bear registration-related expenses but will not receive any proceeds from the selling securityholder’s sales. As of March 31, 2026, Twist had 62,154,412 shares of common stock outstanding, separate from this resale amount. The filing also renews registration after a prior automatic shelf on Form S-3 expired under Rule 415(a)(5).
Twist Bioscience Corp (TWST) received a notice of proposed sale of restricted common stock for the account of Dennis H. Cho, who is listed as an officer. The notice covers up to 14,205 shares of common stock to be sold through Fidelity Brokerage Services LLC, with an indicated aggregate market value of $1,843,098.75. Twist Bioscience had 62,707,424 shares of common stock outstanding as of August 19, 2026. The notice also lists previously vested restricted stock awards and several common stock sales by Cho over the prior three months.